dc.contributor.author | Plaza Díaz, Julio | |
dc.contributor.author | Álvarez Mercado, Ana Isabel | |
dc.date.accessioned | 2020-12-18T12:02:58Z | |
dc.date.available | 2020-12-18T12:02:58Z | |
dc.date.issued | 2020-11-07 | |
dc.identifier.citation | Plaza-Díaz, J., Solís-Urra, P., Rodríguez-Rodríguez, F., Olivares-Arancibia, J., Navarro-Oliveros, M., Abadía-Molina, F., & Álvarez-Mercado, A. I. (2020). The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. International Journal of Molecular Sciences, 21(21), 8351. [doi:10.3390/ijms21218351] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/65034 | |
dc.description.abstract | Liver disease encompasses pathologies as non-alcoholic fatty liver disease, non-alcoholic
steatohepatitis, alcohol liver disease, hepatocellular carcinoma, viral hepatitis, and autoimmune
hepatitis. Nowadays, underlying mechanisms associating gut permeability and liver disease
development are not well understood, although evidence points to the involvement of intestinal
microbiota and their metabolites. Animal studies have shown alterations in Toll-like receptor
signaling related to the leaky gut syndrome by the action of bacterial lipopolysaccharide. In humans,
modifications of the intestinal microbiota in intestinal permeability have also been related to liver
disease. Some of these changes were observed in bacterial species belonging Roseburia, Streptococcus,
and Rothia. Currently, numerous strategies to treat liver disease are being assessed. This review
summarizes and discusses studies addressed to determine mechanisms associated with the microbiota
able to alter the intestinal barrier complementing the progress and advancement of liver disease,
as well as the main strategies under development to manage these pathologies. We highlight those
approaches that have shown improvement in intestinal microbiota and barrier function, namely
lifestyle changes (diet and physical activity) and probiotics intervention. Nevertheless, knowledge
about how such modifications are beneficial is still limited and specific mechanisms involved are not
clear. Thus, further in-vitro, animal, and human studies are needed. | es_ES |
dc.description.sponsorship | National Agency for Research and Development (ANID) BECAS Chile
72180543 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Mdpi | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Liver diseases | es_ES |
dc.subject | Intestinal barrier | es_ES |
dc.subject | Intestinal permeability | es_ES |
dc.subject | Microbiota | es_ES |
dc.title | The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/ijms21218351 | |
dc.type.hasVersion | VoR | es_ES |